Infliximab and ulcerative colitis

Bibliography

• PODOLSKY D: Inflammatory bowel disease. N. Engl. J. Med. (2002) 347:417-429.
   PubMed Web of Science ®Google Scholar
• PENNICA D, NEDWIN GE, HAYFLICK JS et al.: Human tumor necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature (1984) 312:724-729.
   PubMed Web of Science ®Google Scholar
• BRYNSKOV J, FOEGH P, PEDERSEN G et al.: Tumour necrosis factor alpha converting enzyme (TACE) activity in the colonic mucosa of pts with inflammatory bowel disease. Gut (2002) 51(1):37-43.
   PubMed Web of Science ®Google Scholar
• BLACK RA, RAUCH CT, KOZLOSKY CJ et al.: A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature (1997) 385(6618):729-733.
   PubMed Web of Science ®Google Scholar
• GOETZ FW, PLANAS JV, MACKENZIE S: Tumor necrosis factors. Dev. Comp. Immunol. (2004) 28(5):487-497.
   PubMed Web of Science ®Google Scholar
• LIU ZG, HSU H, GOEDDEL DV, KARIN M: Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-kappaB activation prevents cell death. Cell (1996) 87(3):565-576.
   PubMed Web of Science ®Google Scholar
• VAN DEVENTER SJ: Transmembrane TNF-alpha, induction of apoptosis and efficacy of TNF-alpha targeting therapies in Crohn’s disease. Gastroenterology (2001) 121:1242-1246.
   PubMed Web of Science ®Google Scholar
• WAETZIG GH, SCHREIBER S: Mechanisms of infliximab: the reverse side of a drug effect. Inflamm. Bowel Dis. (2004) 10(Suppl. 1):S38-S43.
   PubMed Web of Science ®Google Scholar
• KIM EY: The HS: critical role of TNF receptor type-2 (p75) as a costimulator for IL-2 induction and T cell survival: a functional link to CD28. J. Immunol. (2004) 173:4500-4509.
   PubMed Web of Science ®Google Scholar
• LUGERING A, SCHMIDT M, LUGERING N et al.: Infliximab induces apoptosis in monocytes from pts with chronic active Crohn’s disease by using a caspase-dependent pathway. Gastroenterology (2001) 121(5):1145-1157.
   PubMed Web of Science ®Google Scholar
• AGNHOLT J, KALTOFT K: Infliximab downregulates interferon-gamma production in activated gut T-lymphocytes from pts with Crohn’s disease. Cytokine (2001) 15(4):212-222.
   PubMed Web of Science ®Google Scholar
• TEN HOVE T, VAN MONTFRANS C, PEPPELENBOSCH MP et al.: Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn’s disease. Gut (2002) 50(2):206-211.
   PubMed Web of Science ®Google Scholar
• WAETZIG GH, SEEGERT D, ROSENSTIEL P et al.: p38 mitogen-activated protein kinase is activated and linked to TNF-alpha signaling in inflammatory bowel disease. J. Immunol. (2002) 168(10):5342-5351.
   PubMed Web of Science ®Google Scholar
• AGNHOLT J, KELSEN J, BRANDSBORG B et al.: Increased production of granulocyte-macrophage colony-stimulating factor in Crohn’s disease-a possible target for infliximab treatment. Eur. J. Gastroenterol. Hepatol. (2004) 16(7):649-655.
   PubMed Web of Science ®Google Scholar
• NOGUCHI M, HIWATASHI N, LIU ZX et al.: Increased secretion of granulocyte-macrophage colony-stimulating factor in mucosal lesions of inflammatory bowel disease. Digestion (2001) 63(Suppl. 1):32-36.
   PubMed Web of Science ®Google Scholar
• KORZENIK JR, DIECKGRAEFE BK, VALENTINE JF et al.: Salmograstim in active Crohn’s disease. N. Engl. J. Med. (2005) 352:2193-2201.
   PubMed Web of Science ®Google Scholar
• CORNILLIE F, SHEALEY D, D’HAENS G et al.: Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in pts with Crohn’s disease. Aliment. Pharmacol. Ther. (2001) 15:463-473.
   PubMed Web of Science ®Google Scholar
• DI NOTO D, MACE K, DE RITA R et al.: Pharmacokinetics of infliximab, a chimeric monoclonal antibody specific to tumor necrosis factor: clinical studies in rheumatoid arthritis pts. American Association of Pharmaceutical Scientists Annual Meeting (1999):Abstract 4733.
   Google Scholar
• KAVANAUGH A, ST CLAIR EW, MCCUNE WJ et al.: Chimeric anti-tumor necrosis factor alpha monoclonal antibody treatment of pts with rheumatoid arthritis receiving methotrexate therapy. J. Rheumatol. (2000) 27:841-850.
   PubMed Web of Science ®Google Scholar
• BOUMA G, STROBER W: The immunological and genetic basis of inflammatory bowel disease. Nat. Rev. Immunol. (2003) 3:521-533.
   PubMed Web of Science ®Google Scholar
• MURCH SH, LAMKIN VA, SAVAGE MO et al.: Serum concentrations of tumor necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut (1991) 32(8):913-917.
   PubMed Web of Science ®Google Scholar
• BRAEGGER CP, NICHOLLS S, MURCH SH et al.: Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet (1992) 339(8785):89-91.
   PubMed Web of Science ®Google Scholar
• MURCH SH, BRAEGGER CP, WALKER-SMITH J et al.: Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. Gut (1993) 34(12):1705-1709.
   PubMed Web of Science ®Google Scholar
• HADZISELIMOVIC F, EMMONS LR, GALLATI H: Soluble tumour necrosis factor receptors p55 and p75 in the urine monitor disease activity and the efficacy of treatment of inflammatory bowel disease. Gut (1995) 37(2):260-263.
   PubMed Web of Science ®Google Scholar
• FOGH P, ELLERVIK C, SAERMARK T et al.: TNF-alpha-converting enzyme activity in colonic biopsy specimens from pts with inflammatory bowel disease revealed by mRNA and in vitro assay. Ann. NY Acad. Sci. (1999) 878:692-695.
   PubMed Web of Science ®Google Scholar
• MIZOGUCHI E, MIZOGUCHI A, TAKEDATSU H et al.: Role of tumor necrosis factor receptor 2 (TNFR2) in colonic epithelial hyperplasia and chronic intestinal inflammation in mice. Gastroenterology (2002) 122(1):134-144.
   PubMed Web of Science ®Google Scholar
• WATKINS PE, WARREN BF, STEPHENS S et al.: Treatment of UC in the cottontop tamarin using antibody to tumor necrosis factor alpha. Gut (1997) 40(5):628-633.
   PubMed Web of Science ®Google Scholar
• FAUBION WA JR, LOFTUS EV, HARMSEN et al.: The natural history of inflammatory bowel disease: a population-based study. Gastroenterology (2002) 123:393-395.
   Google Scholar
• VAN ASSCHE G, VERMEIRE S, RUTGEERTS P: Medical treatment of inflammatory bowel diseases. Curr. Opin. Gastroenterol. (2005) 21(4):443-447.
   PubMed Web of Science ®Google Scholar
• LICHTIGER S, PRESENT DH, KORNBLUTH A et al.: Cyclosporine in severe UC refractory to steroid therapy. N. Engl. J. Med. (1994) 330:1841-1845.
   PubMed Web of Science ®Google Scholar
• COHEN RD, STEIN R, HANAUER SB: Intravenous cyclosporine in UC: a five-year experience. Am. J. Gastroenterol. (1999) 94:1587-1592.
   PubMed Web of Science ®Google Scholar
• TARGAN SR, HANAUER SB, VAN DEVENTER SJ et al.: A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease cA2 study group. N. Engl. J. Med. (1997) 337:1029-1035.
   PubMed Web of Science ®Google Scholar
• RUTGEERTS P, D’HAENS G, TARGAN S et al.: Efficacy and safety of retreatment with anti-tumor necrosis factor antibody infliximab to maintain remission in Crohn’s disease. Gastroenterology (1999) 117:761-769.
   PubMed Web of Science ®Google Scholar
• SANDS B, TREMAINE WJ, SANDBORN WJ et al.: Infliximab in the treatment of severe-steroid-refractory UC: a pilot study. Inflamm. Bowel Dis. (2001) 7(2):83-88.
   PubMed Web of Science ®Google Scholar
• SU C, SALZBERG B, LEWIS J, DEREN J et al.: Efficacy of anti-tumor necrosis factor therapy in pts with UC. Am. J. Gastroenterol. (2002) 97:2577-2584.
   PubMed Web of Science ®Google Scholar
• KASER A, MAIRINGER T, VOGEL W et al.: Infliximab in severe steroid refractory UC: a pilot study. Wien. Klin. Wochenschr. (2001) 113:930-933.
   PubMed Web of Science ®Google Scholar
• KOHN A, PRANTERA C, PERA A et al.: Anti-tumor necrosis factor alpha (infliximab) in the treatment of severe UC: a result of an open study on 13 patients. Dig. Liver Dis. (2002) 34(9):626-630.
   PubMedGoogle Scholar
• ACTIS GC, BRUNO M, PINNA-PINTOR P et al.: Infliximab for treatment of steroid-refractory UC. Dig. Liver Dis. (2002) 34:631-634.
   PubMedGoogle Scholar
• GORNET JM, COUVE S, HASSANI Z et al.: Infliximab for refractory UC or indeterminate UC:an open-label multicentre study. Aliment. Pharmacol. Ther. (2003) 18:175-181.
   PubMed Web of Science ®Google Scholar
• PROBERT CS, HEARING SD, SCHREIBER S et al.: Infliximab in moderately severe glucocorticoid resistant UC: a randomized controlled trial. Gut (2003) 52:998-1002.
   PubMed Web of Science ®Google Scholar
• JARNEROT G, HERTERVIG E, FRIIS-LIBY I et al.: Infliximab as rescue therapy in severe-moderate UC: a randomized placebo-controlled trial. Gastroenterology (2005) 128(7):1805-1811.
   PubMed Web of Science ®Google Scholar
• SEO M, OKADA M, YAO T et al.: An index of disease activity in patients with UC. Am. J. Gastroenterol. (1992) 87:971-976.
   PubMed Web of Science ®Google Scholar
• LJUNG T, KARLEN P, SCHMIDT D et al.: Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut (2003) 53:849-843.
   Web of Science ®Google Scholar
• BERMEJO F, LOPEZ-SANROMAN A, HINOJOSA J et al.: Infliximab induces clinical, endoscopic and histological responses in refractory UC. Rev. Esp. Enferm. Dig. (2004) 96(2):94-101.
   PubMed Web of Science ®Google Scholar
• CHEY WY: Infliximab for pts with refractory UC. Inflamm. Bowel Dis. (2001) 7(Suppl. 1):S30-S33.
   PubMed Web of Science ®Google Scholar
• KOUNTOURAS J, ZAVOS C, CHATZOPOULOS D: Anti-tumor necrosis factor therapy for UC. Gastroenterol. (2005) 129:1138-1139.
   PubMed Web of Science ®Google Scholar
• ARMUZZI A, DE PASCALIS B, LUPASCU A et al.: Infliximab in the treatment of steroid-dependent UC. Eur. Rev. Med. Pharmacol. Sci. (2004) 8(5):231-233.
   PubMedGoogle Scholar
• RUTGEERTS P, SANDBORN W, FEAGAN B et al.: Infliximab for induction and maintenance therapy. N. Engl. J. Med. (2005) 353:242-2476.
   Google Scholar
• HANAUER SB, FEAGAN BG, LICHTENSTEIN GR et al.: Maintenance infliximab therapy for Crohn’s disease: the ACCENT 1 randomized trial. Lancet (2002) 359:1541-1549.
   PubMed Web of Science ®Google Scholar
• SANDS BE, ANDERSON FH, BERNSTEIN CN et al.: Infliximab maintenance therapy for fistulizing Crohn’s disease. N. Engl. J. Med. (2004) 350:876-875.
   PubMed Web of Science ®Google Scholar
• OCHSENKUHN T, SACKMANN, GOKE B: Infliximab for acute not steroid-refractory ulcerative colitis: a randomized pilot study. Eur. J. Gastroenterol. Hepatol. (2004) 16:1167-1171.
   PubMed Web of Science ®Google Scholar
• SANDBORN WJ: Pouchitis in the Koch continent ileostomy and the ileo-anal pouch. Gastroenterology (1994) 107:1856-1860.
   PubMed Web of Science ®Google Scholar
• PATEL RT, BAIN I, YOUNGS D et al.: Cytokine production in pouchitis is similar to that in UC. Dis. Colon Rectum (1995) 38:831-834.
   PubMed Web of Science ®Google Scholar
• ARNOTT ID, MCDONALD D, WILLIAMS A et al.: Clinical use of infliximab in Crohn’s disease: the Edinburgh experience. Aliment. Pharmacol. Ther. (2001) 15:1639-1646.
   PubMed Web of Science ®Google Scholar
• VISCIDO A, HABIB FI, KOHN A et al.: Infliximab in refractory pouchitid complicated by fistulae following ileo-anal pouch for UC. Aliment. Pharmacol. Ther. (2003) 17:1263-1127.
   PubMed Web of Science ®Google Scholar
• TREEM WR, COHEN J, DAVIS PM et al.: Cyclosporine fort he treatment of fulminant UC in children. Immediate response, long term results and impact on surgery. Dis. Colon Rectum (1995) 38:474-479.
   PubMed Web of Science ®Google Scholar
• CRANDALL WV, MACKNER LM: Infusion reaction to infliximab in children and adolescents: frequency, outcome and a predictive model. Aliment. Pharmacol. Ther. (2003) 17:75-84.
   PubMed Web of Science ®Google Scholar
• SERRANO MS, SCHMIDT-SOMMERFIELD E, KILBAUGH TJ et al.: Use of infliximab in pediatric pts with inflammatory bowel disease. Ann. Pharmacother. (2001) 35:823-828.
   PubMed Web of Science ®Google Scholar
• MAMULA P, MARKOWITZ JE, BROWN KA et al.: Infliximab as a novel therapy for pediatric UC. J. Pediatr. Gastroenterol. Nutr. (2002) 34:307-311.
   PubMed Web of Science ®Google Scholar
• MAMULA P, MARKOWITZ JE, COHEN LJ et al.: Infliximab in pediatric UC: two-year follow-up. J. Pediatr. Gastroenterol. Nutr. (2004) 38(3):298-301.
   PubMed Web of Science ®Google Scholar
• FRIESEN CA, CALABRO C, CHRISTENSON K et al.: Roberts CC. Safety of infliximab treatment in pediatric pts with inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. (2004) 39(3):265-269.
   PubMed Web of Science ®Google Scholar
• RUSSELL G, KATZ A: Infliximab is effective in acute but not chronic childhood UC. J. Pediatr. Gastroenterol. Nutr. (2004) 39:166-170.
   PubMed Web of Science ®Google Scholar
• EIDELWEIN A, CUFFARI C, ABADOM V et al.: Infliximab efficacy in pediatric UC. Inflamm. Bowel Dis. (2005) 11:213-218.
   PubMed Web of Science ®Google Scholar
• COLOMBEL JF, LOFTUS E, TREMAINE W et al.: The safety profile of infliximab in pts with Crohn’s disease:the Mayo Clinic Experience in 500 pts. Gastroenterology (2004) 126:19-31.
   PubMed Web of Science ®Google Scholar
• BIANCONE L, ORLANDO A, KOHN A et al.: Infliximab and newly diagnosed neoplasia in Crohn’s disease: a multicentre matched pair study. Gut (2006) 55(2):228-233.
   PubMed Web of Science ®Google Scholar
• BAERT F, NOMAN M, VERMEIRE S et al.: Influence of immunogenicity on the long term-efficacy of infliximab in Crohn’s disease. N. Engl. J. Med. (2003) 348:601-608.
   PubMed Web of Science ®Google Scholar